In particular, for DR5 activation, a colon cancer xenograft model has been developed to assess the efficacy and pharmacokinetic profile of a DR5 ligand, a genetically modified DR5-B variant selective for DR5 (Gasparian et al., 2009), revealing dual pro-tumoral and antitumoral effects related to the concentration and mode of administration (Yagolovich et al., 2020). The gene discussed is TNFRSF10B; the disease is colonic neoplasm.